透析的肾衰竭患者使用盐皮质激素受体拮抗剂的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入14项随机对照试验共1309例透析的肾衰竭患者,评估盐皮质激素受体拮抗剂对比安慰剂或不治疗的疗效与安全性。结果显示盐皮质激素受体拮抗剂与较低的心血管死亡(RR 0.41,95%CI 0.24-0.70,P=0.001)和全因死亡(RR 0.44,95%CI 0.30-0.66,P<0.001)相关,高钾血症风险与对照组相当(RR 1.12,95%CI 0.91-1.36,P=0.29)。
要点
- 透析的肾衰竭患者使用盐皮质激素受体拮抗剂可降低心血管死亡和全因死亡风险。
- 高钾血症风险与对照组相比无显著增加。
- 非致死性心血管事件、卒中、血压及心脏功能参数未见显著改善。
核心结论
- 盐皮质激素受体拮抗剂可能改善透析的肾衰竭患者的临床结局,且不显著增加高钾血症风险。
研究设计与样本
- 系统综述与荟萃分析纳入2005至2020年发表的14项随机对照试验,共1309例透析的肾衰竭患者,比较盐皮质激素受体拮抗剂与安慰剂或不治疗。
主要发现
- 盐皮质激素受体拮抗剂与较低的心血管死亡相关(RR 0.41,95%CI 0.24-0.70,P=0.001),证据质量高。
- 盐皮质激素受体拮抗剂与较低的全因死亡相关(RR 0.44,95%CI 0.30-0.66,P<0.001)。
- 高钾血症风险与对照组相当(RR 1.12,95%CI 0.91-1.36,P=0.29)。
- 非致死性心血管事件和卒中未见显著下降,血压及左心室射血分数、左心室质量指数等心脏性能参数未见显著改善。
临床怎么用
- 在透析的肾衰竭患者中,可考虑使用盐皮质激素受体拮抗剂以降低死亡风险,但需监测高钾血症。
- 盐皮质激素受体拮抗剂对非致死性心血管事件、卒中及心脏功能参数无明显改善作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with kidney failure have a high risk of cardiovascular disease due to cardiac remodeling, left ventricular fibrosis, and hyperaldosteronism, all of which can be potentially mitigated by mineralocorticoid receptor antagonists. However, because of the fear of hyperkalemia, the use of mineralocorticoid receptor antagonists in patients with kidney failure is limited in current clinical practice, and few studies have investigated the efficacy and safety. Thus, we aimed to determine the benefits and side effects of mineralocorticoid receptor antagonists in patients with kidney failure treated with dialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a systematic review and meta-analysis of randomized controlled trials published from 2005 to 2020 that compared the effect of mineralocorticoid receptor antagonists with either placebo or no treatment in patients with kidney failure. Two reviewers independently searched the PubMed, EMBASE, and Cochrane databases for all published studies, extracted data, assessed the risk of bias, and rated the quality of evidence. A meta-analysis was conducted on 14 eligible randomized controlled trials, and a total of 1309 patients were included. RESULTS: High-quality evidence suggested that mineralocorticoid receptor antagonists are associated with lower cardiovascular mortality (relative risk, 0.41; 95% confidence interval, 0.24 to 0.70; P=0.001) and all-cause mortality (relative risk, 0.44; 95% confidence interval, 0.30 to 0.66; P<0.001), and the risk of hyperkalemia was comparable with that of control group (relative risk, 1.12; 95% confidence interval, 0.91 to 1.36; P=0.29). However, no significant decrease in nonfatal cardiovascular events and stroke was observed, and there was no significant improvement in BP or cardiac performance parameters, including left ventricular ejection fraction and left ventricular mass index. CONCLUSIONS: Our meta-analysis suggests that mineralocorticoid receptor antagonists might improve clinical outcomes of patients with kidney failure without significant increase in the risk of hyperkalemia.
引用
- Chen KT, Kang YN, Lin YC, et al. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2021. PMID: 34117083. doi:10.2215/CJN.15841020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。